[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Makhdoomi KR, Huntly BJ, Diggory RT: Immunosuppressive drug therapy as a potentiator of anal carcinoma in a patient with relapsing lymphoma. J Pak Med Assoc; 2000 Jan;50(1):37-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunosuppressive drug therapy as a potentiator of anal carcinoma in a patient with relapsing lymphoma.
  • [MeSH-major] Anus Neoplasms / etiology. Hodgkin Disease / complications

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10770048.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] PAKISTAN
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


2. Matsuo S, Mizuta Y, Hayashi T, Susumu S, Tsutsumi R, Azuma T, Yamaguchi S: Mucosa-associated lymphoid tissue lymphoma of the transverse colon: a case report. World J Gastroenterol; 2006 Sep 14;12(34):5573-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue lymphoma of the transverse colon: a case report.
  • We herein present a case of a 75-year-old female with mucosa-associated lymphoid tissue (MALT) lymphoma of the transverse colon with the stage IE (Ann Arbor classification).
  • Colonoscopy revealed the tumor's appearance as a IIa plus II c-like early colon cancer as defined according to the macroscopic classification of the Japanese Research Society for Cancer of Colon, Rectum and Anus, measuring less than 2 cm in diameter.
  • Histologically, the tumor was diagnosed as MALT lymphoma because of the presence of lymphoepithelial lesions consisting of diffuse proliferation of atypical lymphocytes and glandular destruction.
  • The patient first underwent H pylori eradication therapy with Lansap.
  • The operative procedure included a partial colectomy with dissection of the paracolic lymph nodes.
  • The tumor measured 45 mm multiply 30 mm in diameter and histological examination showed that the lymphoma cells had infiltrated the muscle layer of the colon without nodal involvement.
  • The patient has had no recurrence postoperatively without any chemotherapy.
  • [MeSH-major] Colonic Neoplasms / microbiology. Colonic Neoplasms / surgery. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / surgery
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Colon, Transverse / microbiology. Colon, Transverse / pathology. Colon, Transverse / surgery. Disease Progression. Drug Resistance, Microbial. Female. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):1003-5 [12845967.001]
  • [Cites] Scand J Gastroenterol Suppl. 1988;142:44-9 [3166533.001]
  • [Cites] J Clin Pathol. 1989 Dec;42(12):1269-71 [2613920.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Histopathology. 1994 Apr;24(4):357-62 [8045524.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1624-30 [9193362.001]
  • [Cites] Lancet. 1997 Jul 12;350(9071):115-6 [9228971.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5 [9308704.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Ann Intern Med. 1999 Jul 20;131(2):88-95 [10419446.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):637-45 [10442184.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):514-5 [10465640.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2352-4 [10521996.001]
  • [Cites] J Korean Med Sci. 2005 Apr;20(2):325-8 [15832010.001]
  • [Cites] J Gastroenterol. 2005 Aug;40(8):843-7 [16143891.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1370-5 [16549831.001]
  • [Cites] Gut. 2000 Jan;46(1):133-5 [10601069.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] Gastroenterology. 2000 May;118(5):821-8 [10784580.001]
  • [Cites] Gastrointest Endosc. 2000 Dec;52(6):802-4 [11115928.001]
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • [Cites] Gut. 2001 Oct;49(4):584-7 [11559658.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 1999 Apr;9(2):156-9 [11757546.001]
  • [Cites] Gastrointest Endosc. 2002 Feb;55(2):238-9 [11818929.001]
  • [Cites] Endoscopy. 2002 Apr;34(4):343-6 [11932795.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1267-70 [12352248.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • (PMID = 17007004.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC4088249
  •  go-up   go-down


3. Gates AE, Kaplan LD: AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Williston Park); 2002 May;16(5):657-65; discussion 665, 668-70
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS malignancies in the era of highly active antiretroviral therapy.
  • The introduction of highly active antiretroviral therapy (HAART) has had a dramatic impact on the morbidity and mortality of individuals living with human immunodeficiency virus (HIV).
  • The incidence of Kaposi's sarcoma (KS) and primary central nervous system lymphoma (PCNSL) has dropped precipitously since the introduction of HAART in 1995.
  • Systemic non-Hodgkin's lymphoma (NHL) appears to be declining in incidence as well, but to a lesser degree than KS and PCNSL.
  • The impact of HAART on the epidemiology of other HIV-associated malignancies, including Hodgkin's disease and anal carcinoma, remains unclear.
  • Data regarding the impact of HAART on the natural history and treatment outcomes of HIV-associated malignancies are limited.
  • The possibility of direct and indirect roles of HIV in HIV-related carcinogenesis suggests that antiretroviral therapy may be an important component of the treatment strategy for several HIV-related malignancies.
  • Patients with HIV-NHL treated with HAART in addition to chemotherapy experience fewer intercurrent opportunistic infections.
  • Furthermore, the simultaneous administration of HAART and chemotherapy does not appear to significantly increase toxicity.
  • Whether the combination of HAART and standard therapy results in improved survival remains uncertain.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Anus Neoplasms / complications. Anus Neoplasms / epidemiology. Central Nervous System Neoplasms / epidemiology. Lymphoma, AIDS-Related / epidemiology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Female. Hodgkin Disease / complications. Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Humans. Male


Advertisement
4. Gates AE, Kaplan LD: AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Williston Park); 2002 Apr;16(4):441-51, 456, 459
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS malignancies in the era of highly active antiretroviral therapy.
  • The introduction of highly active antiretroviral therapy (HAART) has had a dramatic impact on the morbidity and mortality of individuals living with human immunodeficiency virus (HIV).
  • The incidence of Kaposi's sarcoma (KS) and primary central nervous system lymphoma (PCNSL) has dropped precipitously since the introduction of HAART in 1995.
  • Systemic non-Hodgkin's lymphoma (NHL) appears to be declining in incidence as well, but to a lesser degree than KS and PCNSL.
  • The impact of HAART on the epidemiology of other HIV-associated malignancies, including Hodgkin's disease and anal carcinoma, remains unclear.
  • Data regarding the impact of HAART on the natural history and treatment outcomes of HIV-associated malignancies are limited.
  • The possibility of direct and indirect roles of HIV in HIV-related carcinogenesis suggests that antiretroviral therapy may be an important component of the treatment strategy for several HIV-related malignancies.
  • Patients with HIV-NHL treated with HAART in addition to chemotherapy experience fewer intercurrent opportunistic infections.
  • Furthermore, the simultaneous administration of HAART and chemotherapy does not appear to significantly increase toxicity.
  • Whether the combination of HAART and standard therapy results in improved survival remains uncertain.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active / adverse effects. Central Nervous System Neoplasms / etiology. Lymphoma, Non-Hodgkin / etiology. Sarcoma, Kaposi / etiology
  • [MeSH-minor] Anus Neoplasms / epidemiology. Anus Neoplasms / etiology. Humans. Immunocompromised Host. Incidence. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / etiology. Risk Factors


5. Freudenberg S, Palma P, Grobholz R, Ngendahayo L, Post S: HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case. Dis Colon Rectum; 2005 Aug;48(8):1656-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.
  • PURPOSE: This article describes and discusses primary Burkitt's lymphoma of the anus which is an extremely rare site of origin.
  • METHODS AND RESULTS: A 38-year-old HIV+ Rwandan farmer had an 8-cm x 13-cm anal tumor.
  • Histopathology and immunohistology provided evidence of an Epstein-Barr virus-associated Burkitt's lymphoma.
  • Chemotherapy in combination of virostatic therapy is the gold standard for treatment, but because of economic constraints surgical treatment was the only practicable intervention and an abdominoperineal resection of the anorectum was performed.
  • CONCLUSIONS: Because of the AIDS epidemic and the increase of anal malignant pathologies, anal Burkitt's lymphoma may appear more frequently.
  • Adequate treatment is available for only a small percentage of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034658.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Bouchardy C, Dehler S, Jundt G, Ess S, Bordoni A, Konzelmann I, Frick H, Dal Maso L, Elzi L, Furrer H, Calmy A, Cavassini M, Ledergerber B, Keiser O, Swiss HIV Cohort Study: Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer; 2010 Jul 27;103(3):416-22
Bern Open Repository and Information System. Free Full text from BORIS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The advent of highly active antiretroviral therapy (HAART) in 1996 led to a decrease in the incidence of Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), but not of other cancers, among people with HIV or AIDS (PWHA).
  • Incidence of cancers of the anus, liver, non-melanomatous skin, and Hodgkin's lymphoma increased in the early- compared with the pre-HAART period, but not during the late-HAART period.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Lymphoma, Non-Hodgkin / epidemiology. Neoplasms / epidemiology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / drug therapy. Adult. Aged. Chromosome Mapping. Cohort Studies. Drug Administration Schedule. Female. HIV Infections / drug therapy. Humans. Incidence. Male. Middle Aged. Sarcoma, Kaposi / epidemiology. Skin Neoplasms / epidemiology. Switzerland / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Non-ARV Adverse Events .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] JAMA. 2008 Aug 6;300(5):555-70 [18677028.001]
  • [Cites] AIDS. 2009 Jan 28;23(3):385-93 [19114864.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):840-7 [19223894.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] AIDS. 2009 Oct 23;23(16):2183-90 [19734774.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Antivir Ther. 2009;14(8):1065-74 [20032536.001]
  • [Cites] Int J Cancer. 2010 Sep 1;127(6):1437-45 [20049835.001]
  • [Cites] J Biomed Inform. 2001 Dec;34(6):387-95 [12198758.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS. 2004 Sep 3;18(13):1835-43 [15316345.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):441 [8094208.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):861-75 [15516959.001]
  • [Cites] AIDS. 2004 Nov 19;18(17):2285-93 [15577541.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] J Viral Hepat. 2007 Mar;14(3):183-8 [17305884.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):215-23 [16395695.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Infect Dis. 2008 Jun 15;197(12):1685-94 [18513155.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • (PMID = 20588274.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2920013
  • [Investigator] Battegay M; Bernasconi E; Böni J; Bucher HC; Bürgisser P; Calmy A; Cavassini M; Dubs R; Egger M; Elzi L; Fischer M; Flepp M; Fontana A; Francioli P; Furrer H; Fux CA; Gorgievski M; Günthard HF; Hirsch HH; Hirschel B; Hösli I; Kahlert C; Kaiser L; Karrer U; Kind C; Klimkait T; Ledergerber B; Martinetti G; Martinez de Tejada B; Müller N; Nadal D; Paccaud F; Pantaleo G; Rauch A; Regenass S; Rickenbach M; Rudin C; Schmid P; Schultze D; Schöni-Affolter F; Schüpbach J; Speck R; Taffé P; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S
  •  go-up   go-down


7. Silverberg MJ, Abrams DI: Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr Opin HIV AIDS; 2009 Jan;4(1):42-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: There is an increasing burden of non-AIDS-defining malignancies (NADMs) in the antiretroviral therapy (ART) era.
  • NADMs associated with immunosuppression included Hodgkin's lymphoma, oral/pharynx, lung, anal, and colorectal cancers.
  • Despite the potential protective effect of ART on some NADMs, recent studies evaluating calendar era trends have noted an increased risk of Hodgkin's lymphoma and anal cancer and no change in risk for lung cancer in the ART era.
  • However, a continued high risk in the ART era for certain cancers have been observed, including Hodgkin's lymphoma and anal cancers.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2007 Jul 15;196(2):304-12 [17570119.001]
  • [Cites] AIDS. 1997 Aug;11(10):1300-1 [9256954.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] AIDS. 1999 Oct 22;13(15):2105-11 [10546864.001]
  • [Cites] JAMA. 1999 Dec 15;282(23):2220-6 [10605973.001]
  • [Cites] AIDS. 1997 Nov;11(13):1653-5 [9365774.001]
  • [Cites] AIDS. 1998 May 7;12(7):F45-9 [9619797.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):207-15 [15621803.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Neoplasia. 2007 Apr;9(4):271-8 [17460771.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5183-94 [17785575.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10920-8 [18006837.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] AIDS Res Hum Retroviruses. 2008 Feb;24(2):163-8 [18240964.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):489-96 [18301061.001]
  • [Cites] Addiction. 2008 Apr;103(4):651-9 [18339110.001]
  • [Cites] AIDS. 2008 Apr 23;22(7):841-8 [18427202.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2699-706 [18509182.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):485-90 [18614916.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):339-54 [18650512.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1251-8 [18618279.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1809-15 [10673996.001]
  • [Cites] Lancet. 2000 Jul 22;356(9226):291-6 [11071184.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):44-9 [11158206.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] Blood. 2002 May 15;99(10):3771-9 [11986235.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5230-5 [12234989.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):384-90 [12447008.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Lancet Oncol. 2003 Sep;4(9):537-47 [12965274.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7426-31 [15492266.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] AIDS. 1997 Feb;11(2):261-2 [9030382.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • (PMID = 19339938.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI068641; United States / NIAID NIH HHS / AI / K01 AI071725; United States / NIAID NIH HHS / AI / U01 AI068641; United States / NIAID NIH HHS / AI / U01 AI068641-03; United States / NIAID NIH HHS / AI / K01AI071725; United States / NIAID NIH HHS / AI / UM1 AI068641; United States / NIAID NIH HHS / AI / AI071725-02; United States / NIAID NIH HHS / AI / AI068641-03; United States / NIAID NIH HHS / AI / K01 AI071725-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS94539; NLM/ PMC2698664
  •  go-up   go-down


8. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomin A, Bellù F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S, Cancer and AIDS Registries Linkage (CARL) Study: Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer; 2009 Mar 10;100(5):840-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A record-linkage study was carried out between the Italian AIDS Registry and 24 Italian cancer registries to compare cancer excess among persons with HIV/AIDS (PWHA) before and after the introduction of highly active antiretroviral therapy (HAART) in 1996.
  • SIR for Kaposi sarcoma (KS) and non-Hodgkin lymphoma greatly decreased in 1997-2004 compared with 1986-1996, but high SIRs for KS persisted in the increasingly large fraction of PWHA who had an interval of <1 year between first HIV-positive test and AIDS diagnosis.
  • A significant excess of liver cancer (SIR=6.4) emerged in 1997-2004, whereas the SIRs for cancer of the cervix (41.5), anus (44.0), lung (4.1), brain (3.2), skin (non-melanoma, 1.8), Hodgkin lymphoma (20.7), myeloma (3.9), and non-AIDS-defining cancers (2.2) were similarly elevated in the two periods.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / epidemiology. Antiretroviral Therapy, Highly Active. Neoplasms / epidemiology. Neoplasms / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):94-100 [12838307.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):181-3 [18684500.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):377-80 [11317082.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] J Biomed Inform. 2001 Dec;34(6):387-95 [12198758.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] AIDS. 2004 Jan 2;18(1):109-13 [15090836.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):441 [8094208.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2005 Jul 1;41(1):124-6; author reply 126-7 [15937776.001]
  • [Cites] AIDS Care. 2006 May;18(4):376-8 [16809116.001]
  • [Cites] Epidemiol Prev. 2006 Jan-Feb;30(1 Suppl 2):8-10, 12-28, 30-101 passim [16826725.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Eur J Cancer Prev. 2006 Dec;15(6):554-6 [17106339.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1085-91 [17349785.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Clin Infect Dis. 2007 Aug 15;45(4):510-3 [17638204.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):282-6 [18845959.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • (PMID = 19223894.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653754
  • [Investigator] Zucchetto A; De Paoli A; Colamartini A; Autelitano M; Crocetti E; Marani E; Fiore AR; Tittarelli A; Rosso S; Rashid I; Donato F; Pezzarossi A; Sgargi P; La Rosa F; Franchini S; Zanier L; Cesaraccio R; Senatore G; Vercellino PC; Vittadello F; Contrino ML; Antonini S; Maspero S; La Rosa MG; Boros S; Salfa MC
  •  go-up   go-down


9. Place RJ, Huber PJ, Simmang CL: Anorectal lymphoma and AIDS: an outcome analysis. J Surg Oncol; 2000 Jan;73(1):1-4; discussion 4-5
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal lymphoma and AIDS: an outcome analysis.
  • BACKGROUND AND OBJECTIVE: Primary lymphoma of the anus is an extremely rare problem.
  • METHODS: Over an 18-year period, we identified 6 patients with AIDS and primary anorectal NHL.
  • No benefit was shown from radiation or chemotherapy in those with "B" symptoms.
  • Younger patients and those without systemic constitutional symptoms of lymphoma do better.
  • One patient without "B" symptoms was able to tolerate his radiation and chemotherapy and is disease free at 10 months.
  • CONCLUSION: Despite traditional non-Hodgkin's lymphoma treatment regimens, our AIDS patients (and those examined in a review of the pertinent literature) with anorectal NHL and "B" symptoms have a poor prognosis.
  • For those without "B" symptoms and who can tolerate the therapy, NHL remission may be obtained.
  • [MeSH-major] Anus Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10649269.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Janas A, Grzesiak-Janas G: [Non-Hodgkin extranodular lymphoma of the palate]. Pol Merkur Lekarski; 2006 Jun;20(120):705-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin extranodular lymphoma of the palate].
  • Less frequent locations are the ovaries, kidneys, adrenal glands, caecum, anus area, and retroperitoneal space.
  • The aim of the study is to present a patient with rarely occuring lymphoma of the soft palate.
  • The result of the examination was: MALT lymphoma, CD20, CD3.
  • The patient was qualified for chemotherapy according to CHOP scheme, in the Chair of Oncology of Medical University in Lodz.
  • The patient completed the treatment in good condition.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Palate, Soft / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007274.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


11. Blackwood L, German AJ, Stell AJ, O'Neill T: Multicentric lymphoma in a dog after cyclosporine therapy. J Small Anim Pract; 2004 May;45(5):259-62
Hazardous Substances Data Bank. KETOCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric lymphoma in a dog after cyclosporine therapy.
  • A clinical diagnosis of anal furunculosis was made, and the dog was treated with cyclosporine and ketoconazole.
  • However, after four weeks of therapy the dog developed multicentric lymphoma.
  • Complete remission was achieved with combination chemotherapy (Wisconsin-Madison protocol).
  • Cyclosporine administration is associated with an increased risk of development of lymphoma in humans and a similar increased risk might be expected in dogs.
  • Although a causative relationship between cyclosporine administration and the development of lymphoma cannot be proven in this case, it is possible that cyclosporine therapy may have contributed to lymphomagenesis.
  • [MeSH-major] Cyclosporine / adverse effects. Dog Diseases / diagnosis. Dog Diseases / etiology. Immunosuppressive Agents / adverse effects. Lymphoma / veterinary
  • [MeSH-minor] Animals. Antifungal Agents / administration & dosage. Anus Diseases / drug therapy. Anus Diseases / veterinary. Blood Cell Count / veterinary. Blood Chemical Analysis / veterinary. Diagnosis, Differential. Dogs. Furunculosis / drug therapy. Furunculosis / veterinary. Ketoconazole / administration & dosage. Male

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15163054.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; R9400W927I / Ketoconazole
  •  go-up   go-down


12. Rakoto-Ratsimba HN, Razafimahandry HJ, Samison LH, Rakotomalala HS, Ranaivozanany A: [A case of anal Burkitt's lymphoma]. Ann Chir; 2003 May;128(4):265-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anal Burkitt's lymphoma].
  • Burkitt non hodgkin lymphoma affects children and young adults.
  • We report a case of anal localisation in a 22 years-old man, human immunodeficiency virus (HIV), negative aiming to show clinical, therapeutical and evolutive particularities of this exceptional localisation.
  • Without chemotherapy, the "natural" evolution was rapidly fatal.
  • Despite the efficacy of nowadays protocols, showing 80% of recovery, this observation illustrates the difficulty of malignant affection's management in developing countries caused by diagnostic delay and high cost of chemotherapy.
  • [MeSH-major] Anus Neoplasms / pathology. Burkitt Lymphoma / pathology. Developing Countries
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / economics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Costs. Humans. Male. Prognosis

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12853026.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Gan JL, Tang ZJ: [Clinical, endoscopic and pathological features of primary colorectal non-Hodgkin lymphoma: 24 cases report]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Nov;9(6):502-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical, endoscopic and pathological features of primary colorectal non-Hodgkin lymphoma: 24 cases report].
  • OBJECTIVE: To investigate the clinical, endoscopic and pathological features in primary colorectal non-Hodgkin lymphoma.
  • METHODS: Twenty-four cases of primary colorectal non-Hodgkin lymphoma were studied retrospectively.
  • The major pathology types were diffuse large B-cell lymphoma (11/24, 45.8%), intestinal T-cell lymphoma (8/24, 33.3%), and mucosa-associated lymphoid tissue lymphoma (MALT) (3/24, 12.5%).
  • Sixteen postoperative patients accepted CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or COP (cyclophosphamide, vincristine, prednisone) chemotherapy, and three patients abandoned treatment.
  • CONCLUSION: The clinical features of primary colorectal non-Hodgkin's lymphoma have no specificity.
  • Diffuse large B-cell lymphoma and intestinal T-cell lymphoma are the main pathological types.
  • Comprehensive treatment of surgery and chemotherapy are effective methods for primary colorectal non-Hodgkin lymphoma.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Endoscopy. Female. Follow-Up Studies. Humans. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143795.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Abid M, Frikha MF, Mdhaffar M, Mzali R, Ben Amar M, Beyrouti MI: [Two pelvic tumors which should not be operated, lymphoma of Burkitt and actinomycosis]. J Chir (Paris); 2009 Jun;146(3):297-300
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two pelvic tumors which should not be operated, lymphoma of Burkitt and actinomycosis].
  • The treatment of the pelvic tumors depends of their histological nature.
  • Some of them require only one medical treatment without recourse to surgery.
  • The evolution was uneventful in the two cases after a medical treatment containing penicillin G or a chemotherapy.
  • We discuss at the time of these two observations the diagnostic difficulties and the therapeutic methods of these rare affections.
  • [MeSH-major] Actinomycosis / therapy. Anus Neoplasms / therapy. Burkitt Lymphoma / therapy. Pelvis

  • Genetic Alliance. consumer health - Anaerobic Actinomyces Infection.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19665710.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP: Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol; 2009 Oct;72(1):10-20
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice.
  • Despite the impact of combined antiretroviral therapy (cART) on human immunodeficiency virus (HIV)-related mortality, malignancies remain the second most common cause of death in HIV infection in developed countries.
  • In addition to the AIDS-defining malignancies, other cancers such as Hodgkin's lymphoma and anal cancer, are more frequent in HIV-infected patients who survive longer even though they do not have complete immune restoration The use of concomitant antineoplastic chemotherapy and cART have been demonstrated to be feasible and effective in patients with HIV-related malignancies; however, many drugs used in cART regimens have the potential for causing drug interactions as a result of their ability to either inhibit or induce the cytochrome P450 (CYP) enzyme system.
  • Since many antineoplastic drugs are also metabolised by the CYP system, co-administration with cART could result in either drug accumulation and possible toxicity, or rapid drug metabolism and decreased efficacy.
  • Unfortunately, very limited prospective interaction data are available to safely guide the combined use of cART and chemotherapy.
  • This paper reviews the potential drug interactions and therapeutic considerations of the antiretroviral agents used to treat HIV and the most common anticancer agents used in the treatment of malignancies found in patients with HIV infection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Neoplasms / drug therapy. Neoplasms / etiology
  • [MeSH-minor] Drug Interactions. Drug Therapy, Combination. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070506.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 77
  •  go-up   go-down


16. Belkacémi Y, Zouhair A, Ozsahin M, Azria D, Mirimanoff RO, Réseau des Cancers Rares (Rare Cancer Network): [Prognostic factors and management of rare cancers]. Cancer Radiother; 2006 Nov;10(6-7):323-9
MedlinePlus Health Information. consumer health - Rare Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Facteurs pronostiques et prise en charge des tumeurs rares.
  • The role of adjuvant therapies, such as chemotherapy and radiation therapy remains unclear.
  • The limited number of patients included in the studies cannot generally allow any consistent statistical analysis to determine either prognostic factors or the impact of surgery and adjuvant therapies on local control and long-term survival.
  • [MeSH-major] Neoplasms / therapy. Rare Diseases / therapy
  • [MeSH-minor] Adenocarcinoma / therapy. Adult. Anus Neoplasms / therapy. Breast Neoplasms / therapy. Central Nervous System Neoplasms / therapy. Cervical Intraepithelial Neoplasia / therapy. Combined Modality Therapy. Female. Humans. Lymphoma / therapy. Male. Plasmacytoma / therapy. Prognosis. Prostatic Neoplasms / therapy. Urogenital Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952474.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


17. Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, Nelson M, Gazzard B: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr; 2004 Dec 15;37(5):1563-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?
  • BACKGROUND: Highly active antiretroviral therapy (HAART) has reduced the incidence and improved the survival of patients with Kaposi sarcoma and AIDS-related non-Hodgkin lymphoma.
  • We wished to evaluate its effects on incidence and survival in HIV-associated anal cancer.
  • METHODS: We measured the incidence and survival of patients with invasive anal cancer from our prospective cohort of 8640 HIV-seropositive individuals.
  • RESULTS: In our cohort of 8640 HIV-seropositive individuals, the incidence of invasive anal cancer (diagnosed in 26 patients) is 60 per 100,000 patient-years.
  • This is 120 times higher than in the age- and gender-matched general population.
  • The incidence of invasive anal cancer in the HIV cohort was 35 (95% confidence interval CI: 15-72) per 100,000 patient-years of follow-up in the pre-HAARTera (1984-1995) and 92 (95% CI: 52-149) per 100,000 patient-years of follow-up in the post-HAARTera (1996-2003) (P > 0.05).
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Antiretroviral Therapy, Highly Active. Anus Neoplasms / epidemiology. HIV Infections / complications. HIV Infections / drug therapy


18. Pantanowitz L, Schlecht HP, Dezube BJ: The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol; 2006 Sep;18(5):469-78
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As HIV-infected individuals live longer due to highly active antiretroviral therapy, their risk of dying from one of these cancers is increased.
  • RECENT FINDINGS: Recent epidemiological studies have identified higher rates of carcinoma of the anus, lung, breast, skin, conjunctiva, liver and prostate; hematopoietic malignancies such as Hodgkin's lymphoma, plasma-cell neoplasia and leukemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients.
  • SUMMARY: It is unclear whether the growing number of reports on non-AIDS-defining cancers reflects a true increased incidence or merely the product of increased surveillance, detection and reporting.
  • Highly active antiretroviral therapy not only promotes longevity in the HIV-positive population, but may increase their risk of developing cancer like Hodgkin's lymphoma.
  • [MeSH-major] HIV Infections / drug therapy. Neoplasms / virology
  • [MeSH-minor] Anti-Retroviral Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Causality. Comorbidity. Humans. Incidence. Risk Factors

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894295.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI 060354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 95
  •  go-up   go-down


19. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA: Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol; 2006 Feb;54(2):189-206; quiz 207-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy.
  • Cutaneous T-cell lymphoma (CTCL) is rare in this population.
  • Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.
  • This article addresses prevention, treatment, and follow-up strategies for this at-risk population.
  • [MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443048.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 274
  •  go-up   go-down


20. Potthoff A, Brockmeyer NH: [HIV-associated tumors]. Hautarzt; 2006 Nov;57(11):988, 990-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While Kaposi sarcoma is seen less frequently since the introduction of antiretroviral therapy, lymphoma and other malignancies are an increasing therapeutic challenge.
  • The incidence of HPV-related anal carcinoma and its precursor lesions is rising so dramatically that screening programs as they are already established for cervical carcinoma should be implemented.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Antiretroviral Therapy, Highly Active. Anus Neoplasms / etiology. Carcinoma, Hepatocellular / etiology. Female. HIV Seropositivity / complications. Humans. Liver Neoplasms / etiology. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Male. Middle Aged. Papillomavirus Infections / complications. Risk Factors. Skin Neoplasms / etiology. Smoking / adverse effects. Uterine Cervical Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1057-61 [8262827.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):603-8 [15793509.001]
  • [Cites] Eur J Med Res. 1999 Dec 16;4(12 ):507-13 [10611054.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):57-9 [11823698.001]
  • [Cites] AIDS. 2003 Nov 7;17(16):2279-90 [14571179.001]
  • [Cites] Eur J Med Res. 1998 Mar 23;3(3):127-47 [9502754.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1526-30 [15083180.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):147-54 [12115328.001]
  • [Cites] Eur J Med Res. 1999 Dec 16;4(12):514-6 [10611055.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1803-9 [12891066.001]
  • [Cites] Eur J Med Res. 1999 Mar 26;4(3):95-100 [10085275.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] Infection. 2005 Jun;33(3):140-7 [15940415.001]
  • [Cites] Cancer Invest. 2001;19(6):573-80 [11486699.001]
  • [Cites] Acta Oncol. 2000;39(2):207-11 [10859012.001]
  • [Cites] J Interferon Cytokine Res. 2002 Mar;22(3):295-303 [12034036.001]
  • [Cites] Hautarzt. 1991 Aug;42(8):492-8 [1717402.001]
  • [Cites] Dtsch Med Wochenschr. 2003 Sep 19;128(38):1957-62 [14502448.001]
  • [Cites] Eur J Med Res. 2005 Jan 28;10(1):43-5 [15737953.001]
  • (PMID = 17036250.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


21. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many previously published cases were likely misdiagnosed examples of non-Hodgkin lymphoma.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • The patients who died thus far had the largest primary tumors.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: state of the art and therapeutic challenges.
  • Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Antiretroviral agents have a propensity for causing drug interactions as a result of their ability to either inhibit or induce the cytochrome P450 (CYP) enzyme system.
  • Because many antineoplastic drugs are also metabolized by the CYP system, coadministration with cART could result in either drug accumulation with increased toxicity, or decreased efficacy of one or both classes of drugs.
  • Further research delineating the combined safety and pharmacokinetics of antiretrovirals and antineoplastic therapy is necessary.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Neoplasms / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


23. Long JL, Engels EA, Moore RD, Gebo KA: Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS; 2008 Feb 19;22(4):489-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incidence of the most common NADC was higher than expected, including cancers of the lung [n = 29; SIR, 5.5; 95% confidence interval (CI), 3.7-8.0], liver (n = 13, SIR, 16.5; 95% CI, 8.8-28.2), anus (n = 10; SIR, 39.0; 95% CI, 18.7-71.7), head and neck (n = 14; SIR, 5.1; 95% CI, 2.8-8.6), and Hodgkin's lymphoma (n = 8; SIR, 9.8; 95% CI, 4.2-19.2).
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Neoplasms / mortality

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] AIDS. 2007 Aug 20;21(13):1711-5 [17690568.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Am J Epidemiol. 2001 Sep 15;154(6):544-56 [11549560.001]
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4):441-51, 456, 459 [12017534.001]
  • [Cites] J Infect Dis. 2002 Oct 1;186(7):1023-7 [12232845.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jun 1;33 Suppl 2:S68-75 [12853855.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Infect Dis. 1999 Mar;179(3):717-20 [9952385.001]
  • [Cites] AIDS. 1999 Oct 1;13(14):1933-42 [10513653.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):121-30 [15561752.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):412-26 [15967835.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] AIDS Patient Care STDS. 2006 May;20(5):318-25 [16706706.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1626-31 [16908796.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 [16878047.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55 [16936558.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):397-406 [16983127.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • (PMID = 18301061.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA016893; United States / NIDA NIH HHS / DA / R01 DA011602-10; United States / NIDA NIH HHS / DA / R01 DA011602; United States / NIDA NIH HHS / DA / K23 DA000523; United States / NIDA NIH HHS / DA / K24 DA000432; United States / NIDA NIH HHS / DA / R01-DA-11602; United States / NIDA NIH HHS / DA / K24-DA00432; United States / NIA NIH HHS / AG / R01 AG026250; United States / NIAID NIH HHS / AI / U01 AI069918; United States / NIDA NIH HHS / DA / K24 DA000432-09; United States / NIDA NIH HHS / DA / K23-DA00523
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS67610; NLM/ PMC2553213
  •  go-up   go-down


24. Yegüez JF, Martinez SA, Sands DR, Sands LR, Hellinger MD: Colorectal malignancies in HIV-positive patients. Am Surg; 2003 Nov;69(11):981-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the development of more effective medications, those infected with HIV are living longer.
  • We included adult patients, with ELISA and Western blot test positive for HIV, and primary malignant tumors located in the colon or rectum.
  • Malignant neoplasms of the anus were excluded for the purposes of this study.
  • Intravenous drug abuse was the main risk factor for HIV.
  • Five out of six patients with ACA had metastatic disease at the time of diagnosis.
  • One patient with stage II ACA developed early liver metastases after colonic resection.
  • These patients developed tumors at earlier ages and were diagnosed at an advanced stage.
  • The use of the new antiretroviral therapy regimens should be further evaluated to know its impact in the survival.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / surgery. Adenocarcinoma / complications. Adult. Aged. Female. Humans. Lymphoma, Non-Hodgkin / complications. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Survival Rate






Advertisement